Drugs / Ankaferd Blood Stopper
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06457360 | Nov 2023 → Jan 2024 | cirrhosis of liver | British University In Egypt | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05438771 | Jun 2021 → Jun 2023 | chemotherapy-induced oral mucositis, chemotherapy-induced toxicity, colorectal cancer | Uludag University | Unknown | No outcome recorded |
| — | NCT06403306 | Apr 2018 | dental pulp disorder, teeth present at birth | Tokat Gaziosmanpasa University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ankaferd Blood Stopper | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06457360 ↗ |
| Known as | ABS | “Ankaferd Blood Stopper (ABS), a standardized mixture of five plants, has been used historically as a haemostatic agent but its mechanism of action remains unknown.” PMID 18304416 ↗ Jan 20081“Ankaferd Blood Stopper (ABS), recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent.” NCT06403306 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Ankaferd Hemostat is a herbal product used as a hemostatic agent in traditional Turkish medicine.” NCT05438771 ↗ |
| Route | Other | “mouth wash” NCT05438771 ↗ |